| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22001 | AS-1269574 Featured | AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays. |
|
| DC11420 | AS-1517499 Featured | AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM. |
|
| DC10086 | AS1842856 Featured | AS1842856 is a potent and cell-permeable Foxo1 inhibitor with an IC50 of 30 nM. |
|
| DC22002 | AS1928370 | AS1928370 (ASP8370) is a potent, selective, orally available TRPV1 antagonist with IC50 of 0.51 uM, shows no inhibitory effects on TRPV4, TRPA11, and TRPM8 at 10 uM. |
|
| DC22766 | AS-1949490 | AS-1949490 (AS1949490) is a potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2. |
|
| DC20682 | AS2521780 | AS2521780 is a potent, selective, orally bioavailable PKCθ inhibitor that inhibits combinant human PKCθ enzyme with IC50 of 0.48 nM, >30-fold higher than other PKC isoforms. |
|
| DC3112 | AS-252424 Featured | AS-252424 is a novel, potent and selective inhibitor of PI3Kγ with IC50 of 33 nM. |
|
| DC20683 | AS2541019 | AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM, >100-fold selectivity over other PI3K isoforms. |
|
| DC20684 | AS2677131 | AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM). |
|
| DC20035 | AS2717638 Featured | AS2717638 is an oral active lysophosphatidic acid receptor 5 (LPA5) antagonist in rodents. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia. |
|
| DC11460 | AS604850 Featured | AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for PI3Kγ than PI3Kα. |
|
| DC7068 | AS605240 | AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα. |
|
| DC11407 | Asapiprant(BGE-175) Featured | Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit |
|
| DC20622 | Asciminib Featured | Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells. |
|
| DC4169 | ASC-J9 | ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors. |
|
| DC1049 | Ascomycin (Immunomycin,FK-520) Featured | Ascomycin is an analog of tacrolimus with immunosuppressive, neurotrophic and antifungal activities. |
|
| DCAPI1060 | L-Ascorbyl 6-palmitate | Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C. |
|
| DC10704 | Asimadoline (EMD-61753) Featured | Asimadoline (EMD-61753) is a drug which acts as a peripherally selective κ-opioid receptor (KOR) agonist. |
|
| DC10781 | ASK1-IN-1 Featured | ASK1-IN-1 is an apoptosis signal regulating kinase 1 (ASK1) inhibitor extracted from patent WO2016025474A1, Compound 4. |
|
| DC21100 | Gusacitinib (ASN-002) Featured | ASN-002 (Gusacitinib, ASN002) is a novel and potent dual inhibitor of SYK/JAK kinases with IC50 of 5-46 nM in biochemical assays. |
|
| DC10558 | ASP 7663 Featured | ASP 7663 is a selective TRPA1 activator (EC50 values are ~0.5 μM in human, mouse and rat). |
|
| DC7359 | Asp-3026 Featured | ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. |
|
| DC20109 | ASP-4058 | ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. |
|
| DC20218 | ASP5878 Featured | ASP5878 is a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance. |
|
| DC23457 | ASP6432 | ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM. |
|
| DC11174 | ASP7657 Featured | ASP7657 (ASP-7657) is a potent, selective, orally active prostaglandin EP4 receptor antagonist with Ki values of 6.02 nM and 2.21 nM for rat and human EP4 receptors, resepctively. |
|
| DC20693 | ASP9436 | ASP9436 (ASP-9436) is a potent, selective brain penetrant and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 8.0 nM, >420-fold selectivity over other PDE subtypes. |
|
| DC10588 | ASP-9521 Featured | ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3. |
|
| DC22003 | Aspacytarabine | Aspacytarabine (Astarabine, BST236) is a cytarabine conjugate that shows anti-neoplastic agents for inhibiting cancer cell growth. . |
|
| DC12360 | Asp-AMS | Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme. |
|
